45
© Springer Nature Singapore Pte Ltd. 2017
S. Sugathan et al. (eds.), Bioresources and Bioprocess in Biotechnology,
DOI 10.1007/978-981-10-4284-3_2
S.S. Kumar
Department of Biotechnology and Microbiology, School of Life Sciences, Kannur University,
Thalassery Campus, Kannur 670661, Kerala, India
S. Abdulhameed (*)
Inter University Centre for Bioscience, Department of Biotechnology and Microbiology,
School of Life Sciences, Kannur University, Kannur, Kerala, India
e-mail: drsabu@gmail.com
2
Therapeutic Enzymes
Swaroop S. Kumar and Sabu Abdulhameed
Abstract
Enzymes as therapeutics hold a few advantages over non-enzymatic drugs with
their amazing specificity towards targets as well as multiple substrate conversion. Development of enzyme therapeutics against rare diseases such as lysosomal storage disorders and severe combined immunodeficiency undoubtedly
raised the hope of patients and improved their quality of life. Development of
enzyme therapeutics against cardiovascular diseases witnessed a tremendous
explosion in the past four to five decades and resulted in the development of the
first approved genetically engineered drug against cardiovascular diseases
(Activase
®
). Since then many recombinant cardiovascular drugs have been
approved for clinical application. Often immunogenicity associated with enzyme
drugs and the cost of production are major setbacks for their development.
Despite their advantages only a few enzymes were approved by the Food and
Drug Administration (FDA).
Keywords
Therapeutic enzymes • Plasminogen activators • Staphylokinase • Nattokinase •
Velaglucerase alfa • Alglucosidase alfa • Serrapeptase • Rasburicase
© Springer Nature Singapore Pte Ltd. 2017
S. Sugathan et al. (eds.), Bioresources and Bioprocess in Biotechnology,
DOI 10.1007/978-981-10-4284-3_2
S.S. Kumar
Department of Biotechnology and Microbiology, School of Life Sciences, Kannur University,
Thalassery Campus, Kannur 670661, Kerala, India
S. Abdulhameed (*)
Inter University Centre for Bioscience, Department of Biotechnology and Microbiology,
School of Life Sciences, Kannur University, Kannur, Kerala, India
e-mail: drsabu@gmail.com
2
Therapeutic Enzymes
Swaroop S. Kumar and Sabu Abdulhameed
Abstract
Enzymes as therapeutics hold a few advantages over non-enzymatic drugs with
their amazing specificity towards targets as well as multiple substrate conversion. Development of enzyme therapeutics against rare diseases such as lysosomal storage disorders and severe combined immunodeficiency undoubtedly
raised the hope of patients and improved their quality of life. Development of
enzyme therapeutics against cardiovascular diseases witnessed a tremendous
explosion in the past four to five decades and resulted in the development of the
first approved genetically engineered drug against cardiovascular diseases
(Activase
®
). Since then many recombinant cardiovascular drugs have been
approved for clinical application. Often immunogenicity associated with enzyme
drugs and the cost of production are major setbacks for their development.
Despite their advantages only a few enzymes were approved by the Food and
Drug Administration (FDA).
Keywords
Therapeutic enzymes • Plasminogen activators • Staphylokinase • Nattokinase •
Velaglucerase alfa • Alglucosidase alfa • Serrapeptase • Rasburicase